AstraZeneca's Recentin fails to show benefit over Roche's Avastin in Phase III colorectal cancer trial
This article was originally published in Scrip
Executive Summary
AstraZeneca is facing more disappointment with the development of its new anticancers after its experimental anti-angiogenic drug Recentin (cediranib) did not show non-inferiority in progression-free survival (PFS), or superiority, to Roche's Avastin (bevacizumab) when both were combined with chemotherapy in the pivotal Phase II/III HORIZON III trial in patients with first-line metastatic colorectal cancer (mCRC).